Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

The Diabetic Retinopathy Study

The Diabetic Retinopathy Study Abstract Diabetic retinopathy has become one of the four most common causes of blindness in the United States.1 Although photocoagulation has been employed in its treatment for more than ten years, its true value remains controversial. In spite of the need for objective, definitive evidence, an adequately controlled study of photocoagulation in the treatment of proliferative diabetic retinopathy has not been performed. This is not surprising, considering the complexity and expense of largescale clinical trials in chronic disease. However, as Inglefinger2 has aptly stated, "When serious diseases are treated by serious methods... then ethical as well as scientific considerations require that medicine depend on the most reliable and the best controlled data available—the kind of data that is sought by randomized clinical study." In keeping with this admonition, a randomized clinical trial of photocoagulation in the treatment of proliferative diabetic retinopathy has been designed and launched. This study References 1. Kahn HA, Moorehead HB: Statistics on Blindness in the Model Reporting Area, 1969-70 , publication 73-427. US Dept of Health, Education, and Welfare, National Institutes of Health, 1973. 2. Inglefinger FJ: The randomized clinical trial . N Engl J Med 287:100-101, 1972.Crossref http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Archives of Ophthalmology American Medical Association

Loading next page...
 
/lp/american-medical-association/the-diabetic-retinopathy-study-2009qqBJ1Z

References (3)

Publisher
American Medical Association
Copyright
Copyright © 1973 American Medical Association. All Rights Reserved.
ISSN
0003-9950
eISSN
1538-3687
DOI
10.1001/archopht.1973.01000050349001
Publisher site
See Article on Publisher Site

Abstract

Abstract Diabetic retinopathy has become one of the four most common causes of blindness in the United States.1 Although photocoagulation has been employed in its treatment for more than ten years, its true value remains controversial. In spite of the need for objective, definitive evidence, an adequately controlled study of photocoagulation in the treatment of proliferative diabetic retinopathy has not been performed. This is not surprising, considering the complexity and expense of largescale clinical trials in chronic disease. However, as Inglefinger2 has aptly stated, "When serious diseases are treated by serious methods... then ethical as well as scientific considerations require that medicine depend on the most reliable and the best controlled data available—the kind of data that is sought by randomized clinical study." In keeping with this admonition, a randomized clinical trial of photocoagulation in the treatment of proliferative diabetic retinopathy has been designed and launched. This study References 1. Kahn HA, Moorehead HB: Statistics on Blindness in the Model Reporting Area, 1969-70 , publication 73-427. US Dept of Health, Education, and Welfare, National Institutes of Health, 1973. 2. Inglefinger FJ: The randomized clinical trial . N Engl J Med 287:100-101, 1972.Crossref

Journal

Archives of OphthalmologyAmerican Medical Association

Published: Nov 1, 1973

There are no references for this article.